Revision as of 22:03, 13 February 2023

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main neuroblastoma page for current regimens.

2 regimens on this page 2 variants on this page

High Risk

COG ANBL0532 Regimen A

Induction,

Chemotherapy, Cycle 1 (CPM + TOPO)

Cyclophosphamide (Cytoxan) by the following weight-based criteria:
- ≤ 12 kg: 13.3 mg/kg iV over 30 to 60 minutes once daily on days 1 through 5
- > 12 kg: 400 mg/m² IV over 30 to 60 minutes once daily on days 1 through 5

Topotecan (Hycamtin) 1.2 mg/m² IV over 30 minutes once daily on days 1 through 5

21 Day Cycle

Chemotherapy, Cycle 2 (CPM + TOPO)

Cyclophosphamide (Cytoxan) by the following weight-based criteria:
- ≤ 12 kg: 13.3 mg/kg iV over 30 to 60 minutes once daily on days 1 through 5
- > 12 kg: 400 mg/m² IV over 30 to 60 minutes once daily on days 1 through 5

Topotecan (Hycamtin) 1.2 mg/m² IV over 30 minutes once daily on days 1 through 5

21 Day Cycle

Supportive Therapy, Cycle 2

Filgrastim (Neupogen) 5 μg/kg SubQ or IV once daily on Day 6 beginning 24 hours after completion of chemotherapy and continuing until ANC > 1000/μL

Filgrastim (Neupogen) 10 μg/kg SubQ or IV once daily beginning once ANC > 1000/μL and continuing until PBSC harvest is complete

PBSC harvest on day 14

21 Day Cycle

Chemotherapy, Cycle 3 (CDDP + ETOP)

Cisplatin (Platinol) by the following weight-based criteria:
- ≤ 12 kg: 1.66 mg/kg IV over 1 hour once daily on days 1 through 4
- > 12 kg: 50 mg/m² IV over 1 hour once daily on days 1 through 4

Etoposide (Vepesid) by the following weight-based criteria:
- ≤ 12 kg: 6.67 mg/kg IV over 1 hour once daily on days 1 through 3
- > 12 kg: 200 mg/m² IV over 1 hour once daily on days 1 through 3

Chemotherapy, Cycle 4 (CPM + DOXO + VCR)

Cyclophosphamide (Cytoxan) by the following weight-based criteria:
- ≤ 12 kg: 70 mg/kg iV over 6 hours once daily on days 1 through 2
- > 12 kg: 2100 mg/m² IV over 6 hours once daily on days 1 through 2

Vincristine (Oncovin) by the following criteria:
- < 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3
- ≥ 12 months and > 12 kg: 0.097 mg/m² or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3
- ≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3

Doxorubicin (Adriamycin) by the following weight-based criteria:
- ≤ 12 kg: 0.83 mg/kg iV over 24 hours once daily on days 1 through 3
- > 12 kg: 25 mg/m² IV over 24 hours once daily on days 1 through 3

21 Day Cycle

Supportive Therapy, Cycle 4 (CPM + DOXO + VCR)

Mesna (Mesnex) by the following weight-based criteria:
- ≤ 12 kg: 14 mg/kg IV over 15 minutes immediately prior to each Cyclophosphamide (Cytoxan) dose and again at 4 and 8 hours after eachCyclophosphamide (Cytoxan) infusion
- > 12 kg: 420 mg/m² IV over 15 minutes immediately prior to each Cyclophosphamide (Cytoxan) dose and again at 4 and 8 hours after eachCyclophosphamide (Cytoxan) infusion

21 Day Cycle

Chemotherapy, Cycle 5 (CDDP + ETOP)

Cisplatin (Platinol) by the following weight-based criteria:
- ≤ 12 kg: 1.66 mg/kg IV over 1 hour once daily on days 1 through 4
- > 12 kg: 50 mg/m² IV over 1 hour once daily on days 1 through 4

Etoposide (Vepesid) by the following weight-based criteria:
- ≤ 12 kg: 6.67 mg/kg IV over 1 hour once daily on days 1 through 3
- > 12 kg: 200 mg/m² IV over 1 hour once daily on days 1 through 3

21 Day Cycle

Chemotherapy, Cycle 6 (CPM + DOXO + VCR)

Cyclophosphamide (Cytoxan) by the following weight-based criteria:
- ≤ 12 kg: 70 mg/kg iV over 6 hours once daily on days 1 through 2
- > 12 kg: 2100 mg/m² IV over 6 hours once daily on days 1 through 2

Vincristine (Oncovin) by the following criteria:
- < 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3
- ≥ 12 months and > 12 kg: 0.097 mg/m² or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3
- ≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 1 through 3

Doxorubicin (Adriamycin) by the following weight-based criteria:
- ≤ 12 kg: 0.83 mg/kg iV over 24 hours once daily on days 1 through 3
- > 12 kg: 25 mg/m² IV over 24 hours once daily on days 1 through 3

21 Day Cycle

Supportive Therapy, Cycle 6 (CPM + DOXO + VCR)

Mesna (Mesnex) by the following weight-based criteria:
- ≤ 12 kg: 14 mg/kg IV over 15 minutes immediately prior to each Cyclophosphamide (Cytoxan) dose and again at 4 and 8 hours after eachCyclophosphamide (Cytoxan) infusion
- > 12 kg: 420 mg/m² IV over 15 minutes immediately prior to each Cyclophosphamide (Cytoxan) dose and again at 4 and 8 hours after eachCyclophosphamide (Cytoxan) infusion

21 Day Cycle

Consolidation,

Chemotherapy, High Dose with PBSC Support

Melphalan (Alkeran) by the following criteria:
- ≤ 12 kg and GFR ≥ 100 mL/min: 2.3 mg/kg IV over 15 to 30 minutes once daily on days -7, -6, -5
- > 12 kg and GFR ≥ 100 mL/min: 70 mg/m² IV over 15 to 30 minutes once daily on days -7, -6, -5
- ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 2 mg/kg IV over 15 to 30 minutes once daily on days -7, -6, -5
- > 12 kg and GFR between 100 mL/min and 60 mL/min: 60 mg/m² IV over 15 to 30 minutes once daily on days -7, -6, -5

Etoposide (Vepesid) by the following criteria:
- ≤ 12 kg and GFR ≥ 100 mL/min: 11.3 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4
- > 12 kg and GFR ≥ 100 mL/min: 338 mg/m² IV over 24 hours once daily on days -7, -6, -5, -4
- ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 6.7 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4
- > 12 kg and GFR between 100 mL/min and 60 mL/min: 200 mg/m² IV over 24 hours once daily on days -7, -6, -5, -4

Carboplatin (Paraplatin) by the following criteria:
- ≤ 12 kg and GFR ≥ 100 mL/min: 14.2 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4
- > 12 kg and GFR ≥ 100 mL/min: 425 mg/m² IV over 24 hours once daily on days -7, -6, -5, -4
- ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 4.1 AUC using Calvert Formula (Max Dose = 300 mg/m²) IV over 24 hours once daily on days -7, -6, -5, -4
- > 12 kg and GFR between 100 mL/min and 60 mL/min: Use the lowest of either 4.1 AUC using Calvert Formula or 10 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4

PBSC on day 0

36 Day Cycle

Supportive therapy,

Filgrastim (Neupogen) 5 μg/kg SubQ or IV once daily starting on day 0 and continuing until post-nadir ANC > 2000/μL for 3 consecutive days

36 Day Cycle

Maintenance, 6 Cycles

Chemotherapy,

Isotretinoin (Accutane) by the following weight-based criteria:
- ≤ 12 kg: 5.33 mg/kg (Round dose to nearest 10 mg) PO twice daily on days 1 through 14
- > 12 kg: 160 mg/m² (Round dose to nearest 10 mg) PO twice daily on days 1 through 14

28 Day Cycle

References

COG ANBL0532:Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013 Jul;48(7):947-52. link to original article link to PMC article PubMed

COG ANBL 0032 Regimen A

Post Consolidation, Study Phase

6 Courses

Chemotherapy

Isotretinoin (Accutane) by the following weight based criteria:
- > 12 kg: 80 mg/m² (Round to nearest 10 mg) PO BID on days 11 through 24
- ≤ 12 kg: 2.67 mg/kg (Round to nearest 10 mg) PO BID on days 11 through 24

25-Day Course

References

COG ANBL0032:Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, SMith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld R, Gillies SD, Cohn SL, Maris JM, Sondel PM. Anti-GD2 Antibody with GM-CSF, IL2, and Isotretinoin for Neuroblastoma. N Engl J Med. 2010 Sep;363(14):1324-34. link to original article link to PMC article PubMed

COG A3973 with Myeloablative Therapy

Induction

Chemotherapy, Cycles 1, 2, 4, and 6

Vincristine (Oncovin) by the following criteria:
- < 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 0 through 2
- ≥ 12 months and > 12 kg: 0.67 mg/m² or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg/m² in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 0 through 2
- ≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 0 through 2

Cyclophosphamide (Cytoxan) by the following weight-based criteria:
- ≤ 12 kg: 70 mg/kg IV over 6 hours once daily on days 0, 1
- > 12 kg: 2100 mg/m² IV over 6 hours once daily on days 0, 1

Doxorubicin (Adriamycin) by the following weight-based criteria:
- ≤ 12 kg: 0.83 mg/kg IV over 24 hours once daily on days 0 through 2
- > 12 kg: 25 mg/m² IV over 24 hours once daily on days 0 through 2

21-Day Cycles

PBSC Harvest occurs on Week 6 of treatment (Cycle 2)

Supportive therapy, Cycle 1, 2, 4, and 6

Mesna (Mesnex) by the following weight-based criteria:
- ≤ 12 kg: 10 mg/kg IV over 15 minutes immediately prior to each Cyclophosphamide (Cytoxan) dose and again at 4 and 8 hours after each Cyclophosphamide (Cytoxan) infusion on days 0, 1
- > 12 kg: 420 mg/m² IV over 15 minutes immediately prior to each Cyclophosphamide (Cytoxan) dose and again at 3, 6, and 9 hours after each Cyclophosphamide (Cytoxan) infusion on days 0, 1

Filgrastim (Neupogen) 5 μg/kg SubQ or IV once daily starting on day 3 and continuing until post-nadir ANC > 1500/μL

21-Day Cycles

Chemotherapy, Cycles 3 and 5

Cisplatin (Platinol) by the following weight-based criteria:
- ≤ 12 kg: 1.66 mg/kg IV over 1 hour once daily on days 0 through 3
- > 12 kg: 50 mg/m² IV over 1 hour once daily on days 0 through 3

Etoposide (Vepesid) by the following weight-based criteria:
- ≤ 12 kg: 6.67 mg/kg IV over 2 hours once daily on days 0 through 2
- > 12 kg: 200 mg/m² IV over 2 hours once daily on days 0 through 2

21-Day Cycles

Supportive therapy, Cycles 3 and 5

Filgrastim (Neupogen) 5 μg/kg SubQ or IV once daily starting on day 4 and continuing until post-nadir ANC > 1500/μL

21-Day Cycles

Consolidation

Carboplatin (Paraplatin) by the following criteria:
- ≤ 12 kg and GFR ≥ 100 mL/min: 14.2 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4
- > 12 kg and GFR ≥ 100 mL/min: 425 mg/m² IV over 24 hours once daily on days -7, -6, -5, -4
- ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: Use the lowest of either 4.1 AUC using Calvert Formula or 10 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4
- > 12 kg and GFR between 100 mL/min and 60 mL/min: 4.1 AUC using Calvert Formula (Max Dose = 300 mg/m²) IV over 24 hours once daily on days -7, -6, -5, -4

Etoposide (Vepesid) by the following criteria:
- ≤ 12 kg and GFR ≥ 100 mL/min: 11.3 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4
- > 12 kg and GFR ≥ 100 mL/min: 338 mg/m² IV over 24 hours once daily on days -7, -6, -5, -4
- ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 6.7 mg/kg IV over 24 hours once daily on days -7, -6, -5, -4
- > 12 kg and GFR between 100 mL/min and 60 mL/min: 200 mg/m² IV over 24 hours once daily on days -7, -6, -5, -4

Melphalan (Alkeran) by the following criteria:
- ≤ 12 kg and GFR ≥ 100 mL/min: 2.3 mg/kg IV over 15 to 30 minutes once daily on days -7, -6, -5
- > 12 kg and GFR ≥ 100 mL/min: 70 mg/m² IV over 15 to 30 minutes once daily on days -7, -6, -5
- ≤ 12 kg and GFR between 100 mL/min and 60 mL/min: 2 mg/kg IV over 15 to 30 minutes once daily on days -7, -6, -5
- > 12 kg and GFR between 100 mL/min and 60 mL/min: 60 mg/m² IV over 15 to 30 minutes once daily on days -7, -6, -5

PBSC on day 0

Maintenance, "Post Consolidation" Isotretinoin

Chemotherapy, 6 Cycles

Isotretinoin (Accutane) by the following weight-based criteria:
- ≤ 12 kg: 5.33 mg/kg (Round dose to nearest 10 mg) PO twice daily on days 1 through 14
- > 12 kg: 160 mg/m² (Round dose to nearest 10 mg) PO twice daily on days 1 through 14

28 Day Cycle

References

COG A3973: SG Kreissman, RC Seeger, KK Matthay, WB London, R Sposto, SA Grupp, DA Haas-Kogan, MP LaQuaglia, A Yu, L Diller, A Buxton, JR Park, SL Cohn, JM Maris, CP Reynolds, JG Villablanca; Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Jul 14;10:999-1008 link to original article link to PubMed link to PMC article
COG A3973: DV Allmen, AM Davidoff, WB London, CV Ryn, DA Haas-Kogan, SG Kreissman, G Khanna, N Rosen, JR Park, MP LaQuaglia; Impact of Extent of Resection on Local Control and Survival in Patients from the COG A3973 Study with High-Risk Neuroblastoma. J Clin Oncol. 2017 Jan 35;2:208-216 link to original article link to PubMed link to PMC article

COG A3973 without Myeloablative Therapy

Induction

Chemotherapy, Cycles 1, 2, 4, and 6

Vincristine (Oncovin) by the following criteria:
- < 12 months: 0.017 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 0 through 2
- ≥ 12 months and > 12 kg: 0.67 mg/m² or 0.022 mg/kg (choose lower dose) (Max Dose of 2 mg/m² in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 0 through 2
- ≥ 12 months and ≤ 12 kg: 0.022 mg/kg (Max Dose of 2 mg in 72 hours) IV over 1 minute or infusion (per institutional policy) once daily before Doxorubicin (Adriamycin) on days 0 through 2

Cyclophosphamide (Cytoxan) by the following weight-based criteria:
- ≤ 12 kg: 70 mg/kg IV over 6 hours once daily on days 0, 1
- > 12 kg: 2100 mg/m² IV over 6 hours once daily on days 0, 1

Doxorubicin (Adriamycin) by the following weight-based criteria:
- ≤ 12 kg: 0.83 mg/kg IV over 24 hours once daily on days 0 through 2
- > 12 kg: 25 mg/m² IV over 24 hours once daily on days 0 through 2

21-Day Cycles

PBSC Harvest occurs on Week 6 of treatment (Cycle 2)

Supportive therapy, Cycle 1, 2, 4, and 6

Mesna (Mesnex) by the following weight-based criteria:
- ≤ 12 kg: 10 mg/kg IV over 15 minutes immediately prior to each Cyclophosphamide (Cytoxan) dose and again at 4 and 8 hours after each Cyclophosphamide (Cytoxan) infusion on days 0, 1
- > 12 kg: 420 mg/m² IV over 15 minutes immediately prior to each Cyclophosphamide (Cytoxan) dose and again at 3, 6, and 9 hours after each Cyclophosphamide (Cytoxan) infusion on days 0, 1

Filgrastim (Neupogen) 5 μg/kg SubQ or IV once daily starting on day 3 and continuing until post-nadir ANC > 1500/μL

21-Day Cycles

Chemotherapy, Cycles 3 and 5

Cisplatin (Platinol) by the following weight-based criteria:
- ≤ 12 kg: 1.66 mg/kg IV over 1 hour once daily on days 0 through 3
- > 12 kg: 50 mg/m² IV over 1 hour once daily on days 0 through 3

Etoposide (Vepesid) by the following weight-based criteria:
- ≤ 12 kg: 6.67 mg/kg IV over 2 hours once daily on days 0 through 2
- > 12 kg: 200 mg/m² IV over 2 hours once daily on days 0 through 2

21-Day Cycles

Supportive therapy, Cycles 3 and 5

Filgrastim (Neupogen) 5 μg/kg SubQ or IV once daily starting on day 4 and continuing until post-nadir ANC > 1500/μL

21-Day Cycles

Maintenance, Not eligible for myeloablative therapy

Chemotherapy, 3 Cycles

Cyclophosphamide (Cytoxan) by the following weight-based criteria:
- ≤ 12 kg: 8.33 mg/kg IV over 30 minutes once daily on days 0 through 4
- > 12 kg: 250 mg/m² IV over 30 minutes once daily on days 0 through 4

Topotecan (Hycamtin) by the following weight-based criteria:
- ≤ 12 kg: 0.025 mg/kg IV over 30 minutes once daily on days 0 through 4
- > 12 kg: 0.75 mg/m² IV over 30 minutes once daily on days 0 through 4

21 Day Cycle

Supportive therapy, 3 Cycles

Mesna (Mesnex) by the following weight-based criteria:
- ≤ 12 kg: 1.7 mg/kg IV over 15 minutes immediately prior to each Cyclophosphamide (Cytoxan) dose and again at 4 and 8 hours after each Cyclophosphamide (Cytoxan) infusion on days 0, 1
- > 12 kg: 50 mg/m² IV over 15 minutes immediately prior to each Cyclophosphamide (Cytoxan) dose and again 3 hours after each Cyclophosphamide (Cytoxan) infusion on days 0, 1

Filgrastim (Neupogen) 5 μg/kg SubQ or IV once daily starting on day 5 and continuing until post-nadir ANC > 1500/μL

21-Day Cycles

Maintenance, "Post Maintenance" Isotretinoin

Chemotherapy, 6 cycles

Isotretinoin (Accutane) by the following weight-based criteria:
- ≤ 12 kg: 5.33 mg/kg (Round dose to nearest 10 mg) PO twice daily on days 1 through 14
- > 12 kg: 160 mg/m² (Round dose to nearest 10 mg) PO twice daily on days 1 through 14

28 Day Cycle

References

COG A3973: SG Kreissman, RC Seeger, KK Matthay, WB London, R Sposto, SA Grupp, DA Haas-Kogan, MP LaQuaglia, A Yu, L Diller, A Buxton, JR Park, SL Cohn, JM Maris, CP Reynolds, JG Villablanca; Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Jul 14;10:999-1008 link to original article link to PubMed link to PMC article
COG A3973: DV Allmen, AM Davidoff, WB London, CV Ryn, DA Haas-Kogan, SG Kreissman, G Khanna, N Rosen, JR Park, MP LaQuaglia; Impact of Extent of Resection on Local Control and Survival in Patients from the COG A3973 Study with High-Risk Neuroblastoma. J Clin Oncol. 2017 Jan 35;2:208-216 link to original article link to PubMed link to PMC article

@@ Line 218: / Line 218: @@
 '''21-Day Cycles'''
-===Consolidation, Eligible for myeloablative therapy===
+===Consolidation===
 *[[Carboplatin (Paraplatin)]] by the following criteria:

Difference between revisions of "Neuroblastoma - historical"

Revision as of 22:03, 13 February 2023

High Risk

COG ANBL0532 Regimen A

Induction,

Chemotherapy, Cycle 1 (CPM + TOPO)

Chemotherapy, Cycle 2 (CPM + TOPO)

Supportive Therapy, Cycle 2

Chemotherapy, Cycle 3 (CDDP + ETOP)

Chemotherapy, Cycle 4 (CPM + DOXO + VCR)

Supportive Therapy, Cycle 4 (CPM + DOXO + VCR)

Chemotherapy, Cycle 5 (CDDP + ETOP)

Chemotherapy, Cycle 6 (CPM + DOXO + VCR)

Supportive Therapy, Cycle 6 (CPM + DOXO + VCR)

Consolidation,

Chemotherapy, High Dose with PBSC Support

Supportive therapy,

Maintenance, 6 Cycles

Chemotherapy,

References

COG ANBL 0032 Regimen A

Post Consolidation, Study Phase

Chemotherapy

References

COG A3973 with Myeloablative Therapy

Induction

Chemotherapy, Cycles 1, 2, 4, and 6

Supportive therapy, Cycle 1, 2, 4, and 6

Chemotherapy, Cycles 3 and 5

Supportive therapy, Cycles 3 and 5

Consolidation

Maintenance, "Post Consolidation" Isotretinoin

Chemotherapy, 6 Cycles

References

COG A3973 without Myeloablative Therapy

Induction

Chemotherapy, Cycles 1, 2, 4, and 6

Supportive therapy, Cycle 1, 2, 4, and 6

Chemotherapy, Cycles 3 and 5

Supportive therapy, Cycles 3 and 5

Maintenance, Not eligible for myeloablative therapy

Chemotherapy, 3 Cycles

Supportive therapy, 3 Cycles

Maintenance, "Post Maintenance" Isotretinoin

Chemotherapy, 6 cycles

References

Navigation menu

Search